In this study, we found that MAP17 was also increased in pancreatic adenocarcinoma cells and was associated with a poor prognosis, as patients with higher levels of MAP17 showed decreased survival. This evidence concerns the gene PDZK1IP1 and pancreatic adenocarcinoma.